Clinical Trial Update: Palifermin After Haploidentical PBSCT [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating palifermin after haploidentical peripheral blood stem cell transplantation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Leukemia
• Myelodysplastic Syndrome
• Myelofibrosis
• Non-hodgkin Lymphoma

Drugs mentioned

• Kepivance (Palifermin)

Snippet

Sponsor: European Society for Blood and Marrow Transplantation | Conditions: Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia | Phase 2 | Status: WITHDRAWN